Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Zhizhong Pan†, Jianhong Peng†, Junzhong Lin†, Gong Chen, Xiaojun Wu, Zhenhai Lu, Yuxiang Deng, Yujie Zhao, Qiaoqi Sui and Desen Wan*

Abstract

Background: Although colorectal oligometastases to the liver can potentially be cured with aggressive local ablation, the efficacy of adjuvant chemotherapy (ACT) for such metastasis remains unclear. The present study explored the effects of ACT on patients with colorectal liver oligometastases (CLO) after curative resections and aimed to identify patients who could benefit from ACT.

Methods: We retrospectively analyzed 264 eligible patients with CLO who underwent curative resection between September 1999 and June 2015. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and log-rank test; prognostic factors were also by Cox regression modeling.

Results: Among 264 patients, 200 (75.8%) patients received ACT and 64 (24.2%) did not receive ACT. These two groups did not significantly differ in clinicopathologic characteristics, and had comparable 3-year OS and RFS rates (RFS: 42.1% vs. 45.7%, \( P = 0.588 \); OS: 69.7% vs. 62.7%, \( P = 0.446 \)) over a median follow-up duration of 35.5 months, irrespective of preoperative chemotherapy. ACT markedly improved 3-year OS in high-risk patients with Memorial Sloan-Kettering Cancer Center clinical risk scores (MSKCC-CRS) of 3–5 (68.2% vs. 33.8%, \( P = 0.015 \)), but presented no additional benefit in patients with MSKCC-CRS of 0–2 (72.2% vs. 78.6%, \( P = 0.834 \)). In multivariate analysis, ACT was independently associated with improved OS in patients with MSKCC-CRS of 3–5.

Conclusions: ACT might offer a prognostic benefit in high-risk patients with CLOs after curative liver resection, but not in low-risk patients. Therefore, patients’ risk status should be determined before ACT administration to optimize postoperative therapeutic strategies.

Keywords: Colorectal cancer, Oligometastases, Adjuvant chemotherapy, Liver resection, Benefit
Introduction
The liver is the most common site of metastasis in patients with colorectal cancer (CRC). At diagnosis, approximately 25% of patients present with synchronous metastases, and approximately 50% of patients ultimately develop metachronous metastases [1, 2]. Liver resection is the most effective curative treatment for patients with CRC liver metastasis, with a 5-year survival rate of 40%–50% [3, 4]. However, ~60% of patients develop recurrent liver metastases after initial liver resection [5, 6]. Because of this high recurrence rate, adjuvant chemotherapy (ACT) has been investigated for patients with CRC metastasis to the liver. Although several studies have indicated the potential efficacy of ACT in prolonging survival, its benefits had not been definitively shown until now [7–9].

The latest version of the European Society for Medical Oncology Guidelines highlights oligometastatic disease—a disease state that links localized and systemic disease [2]. Notably, oligometastatic disease confined to the liver is potentially curable. Aggressive locally ablative treatments, including liver resection, may prolong survival of patients with colorectal liver oligometastasis (CLO), with a 5-year overall survival (OS) rate of 45.9% as shown in our previous study [10]. Because complete resection is technically easy to perform, with usually good oncologic outcomes, the suitability of ACT for patients with CLO is unclear [2, 11]. Additionally, even among CRC patients with the same disease stage, ACT benefits are determined by such characteristics as preoperative carcinoembryonic antigen (CEA) level, need for emergent surgery, lymphovascular invasion, T stage and lymph node metastasis [12, 13]. To our knowledge, the value of ACT has not been reported for patients who develop CLO after curative resection.

Therefore, the present study explored whether ACT had a survival benefit for patients with CLO who had undergone curative liver resections, with particular respect to patients’ risk classification according to the Memorial Sloan-Kettering Cancer Center clinical risk score (MSKCC-CRS) [14].

Patients and methods
Patient selection
We reviewed medical records of consecutive patients with CRC liver metastases who underwent liver resection between September 1999 and June 2015 at Sun Yat-sen University Cancer Center, China. Patients were included in the present study according to the following criteria: (1) histologically confirmed colorectal adenocarcinoma; (2) preoperative metastases confined to the liver; (3) no more than 5 liver metastases; (4) R0 resection for both primary and metastatic tumors; and (5) a minimum follow-up duration of 3 months. Tumor stage was classified according to the 2010 American Joint Committee on Cancer staging system. Eligible patients’ clinicopathologic data and treatment information were reviewed using an electronic medical record system. All procedures were performed according to the ethical standards of the World Medical Association Declaration of Helsinki of 2013. We obtained approval from the independent ethics committee at Sun Yat-sen University Cancer Center, and requested the informed consents before initial treatments.

Patient treatments
The treatment strategy for every patient in the current study was determined by a multidisciplinary team (MDT) as previously described [15]. Preoperative (neoadjuvant) chemotherapy (NAC) and ACT regimens were determined based on evaluations by oncologists, and included XELOX (130 mg/m² intravenous [i.v.] oxaliplatin on Day 1 and 1000 mg/m² oral capecitabine twice daily on Days 1–14 for a 3-week cycle), FOLFIRI (85 mg/m² i.v. oxaliplatin and 400 mg/m² i.v. leucovorin [LV] on Day 1; 400 mg/m² i.v. 5-fluorouracil (5-FU) on Day 1 and then 1200 mg/m² i.v. 5-FU for Day 1–2 for a 2-week cycle), FOLFIRI (180 mg/m² i.v. irinotecan and 400 mg/m² i.v. LV on Day 1; 400 mg/m² i.v. 5-FU on Day 1 and then 1200 mg/m² i.v. 5-FU for Day 1–2 for a 2-week cycle) and capecitabine (1000 mg/m² oral capecitabine twice daily on Days 1–14 for a 3-week cycle). During NAC, tumor response was assessed using computerized tomography (CT) or magnetic resonance imaging (MRI), by Response Evaluation Criteria in Solid Tumors, version 1.1 [16]. Patients underwent non-anatomical hepatectomy with R0 resection (tumor-free margin > 1 mm). Decisions to use ACT were based on patients’ tolerances and preferences, and was recommended to begin 4–6 weeks after liver resection. Among patients who underwent NAC, their ACT regimens were consistent with NAC.

Risk status assessment
Recurrence risk in patients after liver resection was evaluated by the MSKCC-CRS [14]. The scoring system is based on the following 5 clinical factors: (1) node-positive primary tumor, (2) largest metastasis >5 cm, (3) multiple liver metastases, (4) preoperative CEA level >200 ng/mL, and (5) disease-free interval from primary tumor resection to the diagnosis of liver metastasis <12 months. Based on the number of the risk factors, patients were classified into six risk subgroups (MSKCC-CRS 0–5). Patients with a MSKCC-CRS of 0–2 were classified into the low-risk subgroup, while patients with a MSKCC-CRS of 3–5 were classified into the high-risk subgroup.
Follow-up
Follow-up data were collected from a tracking system. Patients were monitored through subsequent visits every 3 months for the first 2 years and then semiannually for 5 years after liver resection. Evaluations included clinical examination and assessment of CEA and carbohydrate antigen (CA) 19-9 levels, and CT imaging of the chest, abdomen and pelvis at 3, 6, 12, and 18 months, 2 years, and annually thereafter. Liver MRI was used to confirm suspicious lesions indicated on CT or in patients with increased CEA or CA19-9 level but negative CT results. The final follow-up visit occurred in June 2017. OS was defined as the interval from liver resection to the date of death from any cause or the date of last follow-up. Recurrence-free survival (RFS) was defined as the interval from liver resection to the date of disease recurrence, death from disease or last follow-up. Random censoring was applied to patients without recurrence or death at the last follow-up date. Early recurrence was defined as disease recurrence or death within 6 months after liver resection, and late recurrence was defined as disease recurrence or death at least 6 months after liver resection [17, 18].

Statistical analysis
All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS, version 21.0, Chicago, IL, USA) and GraphPad Prism version 6.01 (GraphPad, Inc., USA). Values are shown as median (range) or percentage. Continuous and categorical data were compared with the Mann–Whitney U-test, and the Chi square test or Fisher’s exact test, respectively, as appropriate. OS and RFS rates were estimated with the Kaplan–Meier method; differences between groups were assessed with the log-rank test. Parameters for which $P<0.10$ for OS in univariate Cox models were included $P<0.05$ (two-sided) was considered significant.

Results
Patient characteristics
We reviewed data from 365 patients with CRC liver metastases who underwent liver resections. After excluding patients with extrahepatic disease or incomplete resections, 283 patients were identified for careful review. We then excluded 17 patients with more than 5 liver metastases and 2 patients with follow-up of less than 3 months for a final study cohort of 264 patients. They included 171 (64.8%) men and 93 (35.2%) women, with a median age of 57 years (range 25–85 years). Their primary tumors were located in the colon for 163 (61.7%) patients and rectum for 101 (38.3%) patients (Table 1). Overall, 171 (64.8%) patients had synchronous metastases at the time of diagnosis. Of the 225 (85.2%) patients for whom MSKCC-CRS could be evaluated, 162 (72.0%) were low-risk (MSKCC-CRS 0–2), and 63 (28.0%) were high-risk (MSKCC-CRS 3–5). In total, 122 (46.2%) patients received NAC, including 47 (38.5%) who received FOLFOX, 32 (26.2%) who received XELOX, 36 (29.5%) who received FOLFIRI, and 7 (5.7%) who received capecitabine. Additionally, 200 (75.8%) patients received ACT, including 57 (28.5%) who received FOLFOX, 82 (41.0%) who received XELOX, 46 (23.0%) who received FOLFIRI, and 15 (7.5%) who received capecitabine. The median duration of ACT was 3.0 months (range 1.0–6.0 months).

Relationships of ACT with clinicopathologic characteristics
The ACT and non-ACT groups did not significantly differ in clinicopathologic characteristics (Table 1), or in receiving NAC, or radiological tumor response (Table 2).

Effect of ACT on survival outcomes
After their primary liver resections, all patients were followed up for a median of 35.5 months (range 2.0–126.0 months). Median follow-up time did not significantly differ between the ACT group (36.2 months; range 2.0–126.0 months) and the non-ACT group (30.5 months; range 2.0–117.0 months; $P=0.315$; Table 3). Overall, 157 (59.5%) patients experienced tumor recurrence, and 104 (39.4%) patients died of tumor progression. The ACT and non-ACT groups did not significantly differ in postoperative recurrence (60.5% vs. 56.3%, $P=0.547$), early recurrence (24.8% vs. 27.8%, $P=0.718$), or the most common recurrence pattern— intrahepatic metastasis (51.0% vs. 60.9%, $P=0.389$).

Three-year RFS was 43.0%, and OS was 68.1%, for the entire cohort, and did not significantly differ between the ACT and non-ACT groups (RFS: 42.1% vs. 45.7%, $P=0.588$, Fig. 1a; OS: 69.7% vs. 62.7%, $P=0.446$, Fig. 1b). Among patients who received NAC, 3-year RFS and OS rates were not significantly different between the ACT and non-ACT groups (RFS: 27.5% vs. 35.1%, $P=0.621$, Fig. 2a; OS: 59.6% vs. 61.2%, $P=0.674$, Fig. 2b). Likewise, 3-year RFS and OS rates were also comparable between the ACT and non-ACT groups in the absence of NAC (RFS: 56.1% vs. 52.0%, $P=0.747$, Fig. 2c; OS: 79.5% vs. 63.8%, $P=0.265$, Fig. 2d).

The patients were further stratified as high risk for recurrence (MSKCC-CRS 0–2) or low risk (MSKCC-CRS 3–5). Among the low-risk patients, 3-year DFS and OS rates were comparable between the ACT and non-ACT groups (RFS: 50.5% vs. 55.8%, $P=0.709$, Fig. 3a; OS: 72.2% vs. 78.6% $P=0.834$, Fig. 3b). Among the high-risk patients, although no significant difference was found in
**Table 1** Clinicopathologic characteristics of patients with colorectal oligometastasis to the liver after curative liver resection

| Parameters                                      | Total (n) | With ACT (n, %) | Without ACT (n, %) | P value |
|------------------------------------------------|----------|-----------------|--------------------|---------|
| Number of patients                             | 264      | 200             | 64                 |         |
| Age, years                                      |          |                 |                    |         |
| ≤ 60                                           | 164      | 129 (64.5)      | 35 (54.7)          | 0.159   |
| > 60                                           | 100      | 71 (35.5)       | 29 (45.3)          |         |
| Sex                                            |          |                 |                    |         |
| Male                                           | 171      | 128 (64.0)      | 43 (67.2)          | 0.895   |
| Female                                         | 93       | 72 (36.0)       | 21 (32.8)          |         |
| Primary tumor location                         |          |                 |                    |         |
| Colon                                          | 163      | 126 (63.0)      | 37 (57.8)          | 0.457   |
| Rectum                                         | 101      | 74 (37.0)       | 27 (42.8)          |         |
| Primary tumor differentiation                   |          |                 |                    |         |
| Well to moderate                                | 206      | 155 (77.5)      | 51 (79.7)          | 0.713   |
| Poor                                           | 58       | 45 (22.5)       | 13 (20.3)          |         |
| T stage<sup>a</sup>                            |          |                 |                    |         |
| 1–3                                            | 157      | 122 (65.2)      | 35 (66.5)          | 0.707   |
| 4                                              | 86       | 65 (34.8)       | 21 (33.5)          |         |
| N stage<sup>b</sup>                            |          |                 |                    |         |
| 0                                              | 103      | 78 (42.9)       | 25 (45.3)          | 0.814   |
| 1–2                                           | 135      | 104 (57.1)      | 31 (55.4)          |         |
| Timing of metastasis                           |          |                 |                    |         |
| Synchronous                                    | 171      | 136 (68.0)      | 35 (54.7)          | 0.052   |
| Metachronous                                   | 93       | 64 (32.0)       | 29 (45.3)          |         |
| Number of metastatic tumors                    |          |                 |                    |         |
| 1                                              | 140      | 102 (51.0)      | 38 (59.4)          | 0.501   |
| 2–3                                           | 99       | 78 (39.0)       | 21 (32.8)          |         |
| 4–5                                           | 25       | 20 (10.0)       | 5 (7.8)            |         |
| Metastases diameter (cm)<sup>c</sup>           |          |                 |                    |         |
| ≤ 3                                            | 173      | 134 (68.0)      | 39 (61.9)          | 0.371   |
| > 3                                            | 87       | 63 (32.0)       | 24 (38.1)          |         |
| Preoperative CEA (ng/mL)<sup>d</sup>           |          |                 |                    |         |
| ≤ 50                                           | 200      | 156 (81.7)      | 44 (73.3)          | 0.316   |
| > 50                                           | 51       | 35 (18.3)       | 16 (26.7)          |         |
| Preoperative CA19-9 (U/mL)<sup>e</sup>         |          |                 |                    |         |
| ≤ 35                                           | 166      | 128 (68.8)      | 38 (66.7)          | 0.760   |
| > 35                                           | 77       | 58 (31.2)       | 19 (33.3)          |         |
| Preoperative chemotherapy                      |          |                 |                    |         |
| Yes                                            | 122      | 98 (49.0)       | 24 (37.5)          | 0.108   |
| No                                             | 142      | 102 (51.0)      | 40 (62.5)          |         |
| MSKCC-CRS<sup>f</sup>                          |          |                 |                    |         |
| 0–2                                            | 162      | 127 (73.4)      | 35 (67.3)          | 0.390   |
| 3–5                                            | 63       | 46 (26.6)       | 17 (32.7)          |         |

* ACT adjuvant chemotherapy, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score

<sup>a</sup> Data were available for 243 patients

<sup>b</sup> Data were available for 238 patients

<sup>c</sup> Data were available for 260 patients

<sup>d</sup> Data were available for 251 patients

<sup>e</sup> Data were available for 225 patients
| Parameters                                         | With preoperative chemotherapy (n = 122) | P value | Without preoperative chemotherapy (n = 142) | P value |
|--------------------------------------------------|-----------------------------------------|---------|---------------------------------------------|---------|
|                                                  | With ACT (n, %)                         |         | Without ACT (n, %)                          |         |
| Number of patients                               | 98                                      | 24      | 102                                         | 40      |
| Age, years                                       | ≤ 60                                    | 69 (70.4) | 16 (66.7)  | 0.721   | 60 (58.8) | 19 (47.5) | 0.222 |
|                                                  | > 60                                    | 29 (29.6) | 8 (33.3)   |         | 42 (41.2) | 21 (52.5) |       |
| Sex                                              | Male                                    | 65 (66.3) | 17 (70.8) | 0.673   | 63 (61.8) | 26 (65.0) | 0.720 |
|                                                  | Female                                  | 33 (33.7) | 7 (29.2)   |         | 39 (38.2) | 14 (35.0) |       |
| Primary tumor location                           | Colon                                   | 55 (56.1) | 15 (62.5) | 0.571   | 71 (69.6) | 22 (55.0) | 0.100 |
|                                                  | Rectum                                  | 43 (43.9) | 9 (37.5)   |         | 31 (30.4) | 18 (45.0) |       |
| Primary tumor differentiation                     | Well to moderate                        | 72 (73.5) | 20 (83.3) | 0.315   | 83 (81.4) | 31 (77.5) | 0.602 |
|                                                  | Poor                                    | 26 (26.5) | 4 (16.7)   |         | 19 (18.6) | 9 (22.5)  |       |
| T stagea                                         | 1–3                                     | 50 (53.2) | 12 (54.5) | 0.909   | 72 (77.4) | 23 (67.6) | 0.261 |
|                                                  | 4                                       | 44 (46.8) | 10 (45.5) |         | 21 (22.6) | 11 (32.4) |       |
| N stageb                                         | 0                                       | 41 (45.6) | 12 (54.5) | 0.449   | 37 (40.2) | 13 (38.2) | 0.840 |
|                                                  | 1–2                                     | 49 (54.4) | 10 (45.5) |         | 55 (59.8) | 21 (61.8) |       |
| Timing of metastasis                             | Synchronous                             | 74 (75.5) | 15 (62.5) | 0.198   | 62 (60.8) | 20 (50.0) | 0.242 |
|                                                  | Metachronous                            | 24 (24.5) | 9 (37.5)   |         | 40 (39.2) | 20 (50.0) |       |
| Number of metastatic tumors                      | 1                                       | 29 (29.6) | 9 (37.5)   | 0.453   | 73 (71.6) | 29 (72.5) | 0.912 |
|                                                  | 2–5                                     | 69 (70.4) | 15 (62.5) |         | 29 (28.4) | 11 (27.5) |       |
| Metastases diameter (cm)c                        | ≤ 3                                     | 59 (62.1) | 14 (58.3) | 0.735   | 75 (73.5) | 25 (64.1) | 0.270 |
|                                                  | > 3                                     | 36 (37.9) | 10 (41.7) |         | 27 (26.5) | 14 (35.9) |       |
| Preoperative CEA (ng/mL)d                        | ≤ 50                                    | 78 (82.1) | 17 (81.0) | 0.901   | 78 (81.3) | 27 (69.2) | 0.128 |
|                                                  | > 50                                    | 17 (17.9) | 4 (19.0)   |         | 18 (18.8) | 12 (30.8) |       |
| Preoperative CA19-9 (U/mL)e                       | ≤ 35                                    | 70 (76.9) | 15 (75.0) | 1.000   | 58 (61.1) | 23 (62.2) | 0.906 |
|                                                  | > 35                                    | 21 (23.1) | 5 (25.0)   |         | 37 (38.9) | 14 (37.8) |       |
| MSKCC-CRSf                                       | 0–2                                     | 54 (63.5) | 9 (47.4)   | 0.193   | 73 (83.0) | 26 (78.8) | 0.597 |
|                                                  | 3–5                                     | 31 (36.5) | 10 (52.6) |         | 15 (17.0) | 7 (21.2)  |       |
| Preoperative chemotherapy regimen                 | FOLFOX + XELOX                          | 61 (62.2) | 18 (75.0) | 0.503   |         |         |       |
|                                                  | FOLFIRI                                 | 31 (31.6) | 5 (20.8)   |         |         |         |       |
|                                                  | Capecitabine                            | 6 (6.1)   | 1 (4.2)    |         |         |         |       |
| Radiological response to preoperative chemotherapy | PR                                      | 57 (58.8) | 13 (54.2) | 0.683   |         |         |       |
|                                                  | SD                                      | 30 (30.9) | 7 (29.2)   |         |         |         |       |
|                                                  | PD                                      | 10 (10.3) | 4 (16.7)   |         |         |         |       |
Pan et al. Cancer Commun (2018) 38:29

Table 3 Postoperative recurrence in patients with colorectal oligometastases to liver after curative liver resection, with or without adjuvant chemotherapy

| Parameters                  | With ACT (n, %) | Without ACT (n, %) | P value |
|-----------------------------|----------------|-------------------|---------|
| Postoperative recurrence    |                |                   |         |
| (n = 264)                   |                |                   |         |
| Yes                         | 121 (60.5)     | 36 (56.2)         | 0.547   |
| No                          | 79 (39.5)      | 28 (43.8)         |         |
| Recurrence period (n = 157) |                |                   |         |
| Early recurrence            | 30 (24.8)      | 10 (27.8)         | 0.718   |
| Latter recurrence           | 91 (75.2)      | 26 (72.2)         |         |
| Recurrence pattern (n = 127)*|               |                   |         |
| Intrahepatic metastases     | 53 (51.0)      | 14 (60.9)         | 0.389   |
| Extrahepatic metastases     | 51 (49.0)      | 9 (39.1)          |         |

ACT adjuvant chemotherapy

* Data of recurrence pattern were unavailable for 30 patients

3-year DFS rates (25.4% vs. 21.2%, P = 0.978, Fig. 3c), the 3-year OS rate was significantly higher in the ACT group than in the non-ACT group (68.2% vs. 33.8%, P = 0.015, Fig. 3d).

Among high-risk patients, univariate analysis associated ACT with a higher 3-year OS rate (HR: 0.402; 95% CI 0.188–0.858; P = 0.018; Table 4); and multivariate analysis showed ACT (HR: 0.350; 95% CI 0.161–0.759; P = 0.008) and T stage (HR: 2.247; 95% CI 1.093–4.622; P = 0.028) to be independent predictors of higher 3-year OS rates.

Discussion

The efficacy of ACT in prolonging survival of patients after curative resection of CRC liver metastases remains unknown, especially in patients with CLO, who could potentially achieve longer survival after curative treatment. As evidence of whether ACT after curative liver resection is worthwhile is lacking, we investigated the role of ACT in patients with CLO after curative liver resection. Although we saw no significant benefit from ACT on RFS and OS (irrespective of NAC), it notably improved OS in high-risk patients.

Based on the beneficial effects of ACT on patients with resected stage III colon cancer [19, 20], several studies have assessed its efficacy in eliminating micrometastatic disease in patients with CRC liver metastases after liver resection.
resection. The EORTC trial 40983 first showed that perioperative chemotherapy with FOLFOX4 (folinic acid, 5-FU, and oxaliplatin) improved 3-year progression-free survival (PFS) in patients with initially resectable CRC liver metastases who underwent liver resection, compared with surgery alone (HR: 0.73, 95% CI 0.55–0.97, \( P = 0.025 \)) [21]. After a median follow-up of 8.5 years in EORTC trial 40983, the 5-year OS rate was slightly higher in the perioperative chemotherapy group than in the surgery-alone group, but not significantly so (5-year OS rate: 57.3% vs. 54.4%, \( P = 0.350 \)) [7]. However, the potential benefits of NAC and ACT could not be discerned in that setting. Although an analysis of pooled data from the EORTC 40923 trial and FFCD trial 9002 showed potential improvement in the 5-year RFS (36.7% vs. 27.7%, \( P = 0.058 \)) and OS (52.8% vs. 39.6%, \( P = 0.095 \)) in response to ACT with a 5-FU bolus-based regimen in patients after complete resection of CRC liver metastases, the differences between the ACT group and surgery-alone group were non-significant [11]. In the current study, differences between the ACT and non-ACT groups in 3-year RFS (42.1% vs. 45.7%, \( P = 0.588 \)) and OS (69.7% vs. 62.7%, \( P = 0.446 \)) among patients with CLO were smaller than those in the pooled analysis. In addition, ACT did not significantly decrease the rate of postoperative recurrence or affect the recurrence pattern. The selected group of patients in our study experienced favorable survival outcomes after liver resection irrespective of ACT administration (3-year RFS: 43.0% and 3-year OS rates: 68.1%), which implies that ACT has no effect on long-term survival.

NAC has been shown to benefit some patients by allowing conversion to stable or resectable disease, which can translate into better long-term survival [22, 23]. Here, we explored the effect of ACT, with or without NAC, on patient survival. No significant differences were observed in the 3-year RFS and OS between the ACT and non-ACT groups, with or without NAC. Thus, ACT did not provide a survival benefit, irrespective of NAC. Contrary to our results, a recent study by Wang
Fig. 3 Kaplan–Meier survival curves of patients with lower risk (Memorial Sloan-Kettering Cancer Center clinical risk score [MSKCC-CRS] of 0–2) or higher risk (MSKCC-CRS 3–5) for chemotherapy, stratified by the administration of adjuvant chemotherapy (ACT). a Recurrence-free survival (RFS) in the lower-risk group; b overall survival (OS) in the lower-risk group; c RFS in the higher risk group; and d OS in the higher risk group.

Table 4 Univariate and multivariate analyses of prognostic factors for overall survival in patients with MSKCC-CRS 3–5

| Variable                                      | Univariate                  | Multivariate            |
|-----------------------------------------------|-----------------------------|-------------------------|
|                                               | HR (95% CI)                 | P value                 | HR (95% CI)                  | P value |
| Age (≤ 60 years vs. > 60 years)               | 0.945 (0.457–1.955)         | 0.880                   | 2.247 (1.093–4.622)          | 0.028   |
| Sex (male vs. female)                         | 1.014 (0.492–2.090)         | 0.970                   |                              |         |
| Primary tumor location (rectum vs. colon)     | 1.562 (0.754–3.236)         | 0.230                   |                              |         |
| Primary tumor differentiation (poor vs. well to moderate) | 1.601 (0.732–3.502) | 0.160 |                              |         |
| T stage (4 vs. 1–3)                           | 1.957 (0.964–3.973)         | 0.063                   | 2.247 (1.093–4.622)          | 0.028   |
| N stage (positive vs. negative)               | 1.139 (0.345–3.760)         | 0.831                   |                              |         |
| Timing of metastasis (synchronous vs. metachronous) | 1.190 (0.456–3.106) | 0.722 |                              |         |
| Number of metastatic tumors (> 1 vs. 1)       | 0.930 (0.279–3.095)         | 0.906                   |                              |         |
| Metastases diameter (> 3 cm vs. ≤ 3 cm)       | 1.625 (0.795–3.321)         | 0.183                   |                              |         |
| Preoperative CEA (> 50 ng/mL vs. ≤ 50 ng/mL)  | 0.727 (0.334–1.585)         | 0.423                   |                              |         |
| Preoperative CA19-9 (> 35 U/mL vs. ≤ 35 U/mL) | 0.972 (0.444–2.129)         | 0.943                   |                              |         |
| Preoperative chemotherapy (yes vs. no)         | 1.470 (0.687–3.148)         | 0.321                   |                              |         |
| ACT (yes vs. no)                              | 0.402 (0.188–0.858)         | 0.018                   | 0.350 (0.161–0.759)          | 0.008   |

ACT: adjuvant chemotherapy, CA19-9: carbohydrate antigen 19-9, CEA: carcinoembryonic antigen, CI: confidence interval, HR: hazard ratio, MSKCC-CRS: Memorial Sloan-Kettering Cancer Center clinical risk score.
et al. [24] demonstrated the efficacy of ACT in patients with CRC liver metastases who received NAC and liver resection, and suggested that ACT was an effective postoperative management strategy. Notably, the discrepancy in the results between the present study and the study by Wang et al. may be attributable to patient selection and the type of liver resection. In our study, only 28.0% of patients were classified as high-risk group, based on a limited number of liver metastasis, while in the study by Wang et al. 43.3% of patients were identified as high risk. In addition, 23.9% of patients underwent R1 resection in the study by Wang et al. Therefore, these data preliminarily indicate that the benefit of ACT might mainly depend on patients’ risk factors, but not on their acceptance of NAC.

Subgroup analyses based on various risk factors showed that ACT may not be the best treatment strategy for all patients with CLO. The efficacy of ACT was mainly observed in high-risk patients; ACT failed to prolong survival of patients with low risk of recurrence, which was consistent with many previous studies. A study by Rahbari et al. [25] demonstrated that ACT markedly improved survival in high-risk patients with MSKCC-CRS > 2 (HR: 0.40; 95% CI 0.23–0.69, \( P = 0.001 \)), but failed to provide any benefit to patients with a MSKCC-CRS \( \leq 2 \) (HR: 0.90; 95% CI 0.57–1.43, \( P = 0.670 \)). Likewise, ACT provided no benefit for 5-year DFS (55.7% vs. 62.7%, \( P = 0.93 \)) or OS (81.1% vs. 71.7%, \( P = 0.460 \)) in patients with low MSKCC-CRS in the study by Nakai et al. [26]. Interestingly, by examining baseline parameters that predicted beneficial effects of perioperative chemotherapy on PFS in the EORTC 40983 trial, Sorbye et al. [27] demonstrated that patients with higher CEA levels (> 5 ng/mL) had better 3-year PFS than did patients who were treated with surgery alone (35% vs. 20%, \( P = 0.002 \)). Hirokawa et al. [28] also found that ACT increased OS and RFS in 110 patients with CRC liver metastases who underwent initial liver resections and had > 2 risk factors, including H2 classification, invasive tumors (pT4), and positive lymph nodes. Based on the overall results of the study, early engagement by a MDT was needed to carefully evaluate patients’ risk status before receiving ACT, to increase chances of cure [29]. Thus, ACT could be considered a standard treatment strategy after liver resection for high-risk patients, but not for low-risk patients.

The present study had some limitations. First, this retrospective study employed an uncontrolled methodology with a limited number of patients from a single institution. Therefore, the findings need to be validated in a prospective study with a larger sample size. Second, the various ACT regimens and durations might have exerted specific prognostic effects that were not analyzed in the current study [30, 31]. Third, the short follow-up periods were insufficient to evaluate 5-year survival outcomes, and may also have led to underestimation of the effect of ACT on long-term survival. Moreover, the effect of microsatellite instability, and mutations on such biomarkers as KRAS proto-oncogene, NRAS proto-oncogene, B-Raf proto-oncogene, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha on the efficacy of ACT was not assessed in the present study. Future studies should examine these biomarkers. Despite these limitations, our study shows a basis for further clinical trials to evaluate the efficacy of ACT in patients with CLO after curative resection.

Conclusion

ACT provides prognostic benefits in high-risk patients, but not low-risk patients, who develop CLO after undergoing curative liver resection. To optimize use of ACT, patients’ risk status should be determined while forming early management plans. Further prospective studies are warranted to validate our results.

Abbreviations

- S-FU: 5-fluorouracil
- ACT: adjuvant chemotherapy
- CA-19-9: carbohydrate antigen-19-9
- CEA: carcinoembryonic antigen
- CI: confidence interval
- NAC: neoadjuvant chemotherapy
- CT: computerized tomography
- HR: hazard ratio
- LV: leucovorin
- MDT: multidisciplinary team
- MRI: magnetic resonance imaging
- MSKCC-CRS: Memorial Sloan-Kettering Cancer Center clinical risk scores
- CRC: colorectal cancer
- OS: overall survival
- RFS: recurrence-free survival

Authors’ contributions

ZP and JP carried out the data analysis and drafted the manuscript; JP, YD, YZ and QS participated in clinical data collection; GC, XW and ZL supervised the research program and edited the manuscript; DW supervised the research program and edited the manuscript; DW had significant roles in the study design and manuscript review. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank all colleagues of Department of Colorectal Surgery in Sun Yat-sen University Cancer Center, who have involved with performing the treatment for current study.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The key raw data have been deposited into the Research Data Deposit (http://www.researchdata.org.cn), with the Approval Number of RDDA2017000391.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The present study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki of 2013. Informed consents before initial treatment were requested and the study approval
was obtained from independent ethics committees at Sun Yat-sen University Cancer Center.

Funding
The present study was funded by the National Natural Science Foundation of China (No. 81772595), Sun Yat-sen University Clinical Research S010 Program (2015024), Sun Yat-sen University Clinical Research S010 Program (2013013) and Science and Technology Planning Project of Guangdong Province (Grant No. 2013B021800146).

Received: 18 October 2017   Accepted: 8 March 2018

Published online: 29 May 2018

References
1. O'Reilly DA, Poston GJ. Colorectal liver metastases: current and future perspectives. Future Oncol. 2006;2(4):525–31.
2. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
3. Dexein Z, Li R, Ye W, Hafu W, Yunshi Z, Qinghai Y, et al. Outcome of patients with colorectal liver metastasis: analysis of 1613 consecutive cases. Ann Surg Oncol. 2012;19(8):2860–8.
4. Sadot E, Groot KB, Leal JN, Shia J, Gonen M, Allen PJ, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015;262(3):476–85.
5. Chan KM, Wu TH, Cheng CH, Lee WC, Chiang JM, Chen JS, et al. Prognostic significance of the number of tumors and aggressive surgical approach in colorectal cancer hepatic metastasis. World J Surg Oncol. 2014;12:155.
6. D'Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18(4):1096–103.
7. Nordlinger B, Sorbye H, Gilmeilus B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy for FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.
8. Crecoli N, Loupakis F, Antoniotti C, Lenardi S, Masi G, Salvatore L, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015;26(6):1188–94.
9. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(11):38–47.
10. Wang Y, Wang ZQ, Wang FH, Yuan YF, Li BK, Ding PR, et al. The role of adjuvant chemotherapy for colorectal liver metastases after pre-operative chemotherapy: is the treatment worthwhile? J Cancer. 2017;8(7):1179–86.
11. Rahbari NN, Reisfelder C, Schulze-Bergkamen H, Jager D, Buchner MW, Weitz J, et al. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 2014;14:174.
12. Nakai T; Ishikawa H, Tokoid T, Okuno K. The clinical risk score predicts the effectiveness of adjuvant chemotherapy for colorectal liver metastasis. World J Surg. 2015;39(6):1527–36.
13. Sorbye H, Mauer M, Gruenberger T, Gilmeilus B, Poston GJ, Schlag PM, et al. Predictive factors for the benefit of perioperative FOLFOX4 for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 2011;252(5):534–9.
14. Hirokawa F, Hayashi M, Miyamoto Y, Asakuma T, Shimizu T, Kornorka E, et al. Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol. 2014;21(1):139–46.
15. Weiser MR, Jarnagin WR, Saltz LB. Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach? Oncology (Williston Park). 2013;27(11):1074–8.
16. Schmolli HJ, Tabernerio J, Maroun J, de Brui J, Price T, Van Cutsem E, et al. Cetuximab plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.
17. Andre T, Boni C, Navarro M, Tabernerio J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.
18. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;229(3):309–18.
19. Peng J, Li H, Ou Q, Lin J, Wu X, Lu Z, et al. Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival. Oncol Targets Ther. 2017;10:3789–99.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
21. Jung SW, Kim DS, Yu YD, Han JH, Suh SQ. Risk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis. Ann Surg Treat Res. 2016;90(5):257–64.
22. Malik HZ, Gomez D, Wong V, Al-Mukhtar A, Toogood GJ, Lodge JP, et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol. 2007;33(8):1003–9.
23. Haller DG, Tabernerio J, Maroun J, de Brui F, Price T, Van Cutsem E, et al. Cetuximab plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(1):1465–71.